-DOCSTART- -X- O
A -X- _ O
novel -X- _ O
avian -X- _ O
influenza -X- _ O
subtype -X- _ O
, -X- _ O
A -X- _ O
/ -X- _ O
H7N9 -X- _ O
, -X- _ O
emerged -X- _ O
in -X- _ O
2013 -X- _ O
and -X- _ O
represents -X- _ O
a -X- _ O
public -X- _ O
health -X- _ O
threat -X- _ O
with -X- _ O
pandemic -X- _ O
potential. -X- _ O
We -X- _ O
have -X- _ O
previously -X- _ O
shown -X- _ O
that -X- _ O
DNA -X- _ O
vaccine -X- _ O
priming -X- _ O
increases -X- _ O
the -X- _ O
magnitude -X- _ O
and -X- _ O
quality -X- _ O
of -X- _ O
antibody -X- _ O
responses -X- _ O
to -X- _ O
H5N1 -X- _ O
monovalent -X- _ O
inactivated -X- _ O
boost. -X- _ O
We -X- _ O
now -X- _ O
report -X- _ O
the -X- _ O
safety -X- _ O
and -X- _ O
immunogenicity -X- _ O
of -X- _ O
a -X- _ O
H7 -X- _ O
DNA-H7N9 -X- _ O
monovalent -X- _ O
inactivated -X- _ O
vaccine -X- _ O
prime-boost -X- _ O
regimen. -X- _ O
In -X- _ O
this -X- _ O
Phase -X- _ O
1 -X- _ O
, -X- _ O
open -X- _ O
label -X- _ O
, -X- _ O
randomized -X- _ O
clinical -X- _ O
trial -X- _ O
, -X- _ O
we -X- _ O
evaluated -X- _ O
three -X- _ O
H7N9 -X- _ O
vaccination -X- _ O
regimens -X- _ O
in -X- _ O
healthy -X- _ B-Patient
adults -X- _ I-Patient
, -X- _ O
with -X- _ O
a -X- _ O
prime-boost -X- _ O
interval -X- _ O
of -X- _ O
16 -X- _ O
weeks. -X- _ O
Group -X- _ O
1 -X- _ O
received -X- _ O
H7 -X- _ B-Intervention
DNA -X- _ I-Intervention
vaccine -X- _ I-Intervention
prime -X- _ I-Intervention
and -X- _ I-Intervention
H7N9 -X- _ I-Intervention
monovalent -X- _ I-Intervention
inactivated -X- _ I-Intervention
vaccine -X- _ I-Intervention
boost. -X- _ I-Intervention
Group -X- _ O
2 -X- _ O
received -X- _ O
H7 -X- _ B-Intervention
DNA -X- _ I-Intervention
and -X- _ I-Intervention
H7N9 -X- _ I-Intervention
monovalent -X- _ I-Intervention
inactivated -X- _ I-Intervention
vaccine -X- _ I-Intervention
as -X- _ I-Intervention
a -X- _ I-Intervention
prime -X- _ I-Intervention
and -X- _ I-Intervention
H7N9 -X- _ I-Intervention
monovalent -X- _ I-Intervention
inactivated -X- _ I-Intervention
vaccine -X- _ I-Intervention
as -X- _ I-Intervention
a -X- _ I-Intervention
boost. -X- _ I-Intervention
Group -X- _ O
3 -X- _ O
received -X- _ O
H7N9 -X- _ B-Intervention
monovalent -X- _ I-Intervention
inactivated -X- _ I-Intervention
vaccine -X- _ I-Intervention
in -X- _ I-Intervention
a -X- _ I-Intervention
homologous -X- _ I-Intervention
prime-boost -X- _ I-Intervention
regimen. -X- _ I-Intervention
Overall -X- _ O
, -X- _ O
30 -X- _ B-Comparison
individuals -X- _ I-Comparison
between -X- _ I-Comparison
20 -X- _ I-Comparison
to -X- _ I-Comparison
60 -X- _ I-Comparison
years -X- _ I-Comparison
old -X- _ I-Comparison
enrolled -X- _ I-Comparison
and -X- _ I-Comparison
28 -X- _ I-Comparison
completed -X- _ I-Comparison
both -X- _ I-Comparison
vaccinations. -X- _ I-Comparison
All -X- _ O
injections -X- _ O
were -X- _ O
well -X- _ B-Outcome
tolerated -X- _ I-Outcome
with -X- _ I-Outcome
no -X- _ I-Outcome
serious -X- _ I-Outcome
adverse -X- _ I-Outcome
events. -X- _ I-Outcome
2 -X- _ B-Outcome
weeks -X- _ I-Outcome
post-boost -X- _ I-Outcome
, -X- _ I-Outcome
50 -X- _ I-Outcome
% -X- _ I-Outcome
of -X- _ I-Outcome
Group -X- _ I-Outcome
1 -X- _ I-Outcome
and -X- _ I-Outcome
33 -X- _ I-Outcome
% -X- _ I-Outcome
of -X- _ I-Outcome
Group -X- _ I-Outcome
2 -X- _ I-Outcome
achieved -X- _ I-Outcome
a -X- _ I-Outcome
HAI -X- _ I-Outcome
titer -X- _ I-Outcome
â‰¥1:40 -X- _ I-Outcome
compared -X- _ I-Outcome
with -X- _ I-Outcome
11 -X- _ I-Outcome
% -X- _ I-Outcome
of -X- _ I-Outcome
Group -X- _ I-Outcome
3. -X- _ I-Outcome
Also -X- _ O
, -X- _ O
at -X- _ O
least -X- _ O
a -X- _ O
fourfold -X- _ O
increase -X- _ O
in -X- _ O
neutralizing -X- _ O
antibody -X- _ O
responses -X- _ O
was -X- _ O
seen -X- _ O
in -X- _ O
90 -X- _ O
% -X- _ O
of -X- _ O
Group -X- _ O
1 -X- _ O
, -X- _ O
100 -X- _ O
% -X- _ O
of -X- _ O
Group -X- _ O
2 -X- _ O
, -X- _ O
and -X- _ O
78 -X- _ O
% -X- _ O
of -X- _ O
Group -X- _ O
3 -X- _ O
subjects. -X- _ O
Peak -X- _ B-Outcome
neutralizing -X- _ I-Outcome
antibody -X- _ I-Outcome
geometric -X- _ I-Outcome
mean -X- _ I-Outcome
titers -X- _ I-Outcome
were -X- _ I-Outcome
significantly -X- _ I-Outcome
greater -X- _ I-Outcome
for -X- _ I-Outcome
Group -X- _ I-Outcome
1 -X- _ I-Outcome
( -X- _ I-Outcome
GMT -X- _ I-Outcome
= -X- _ I-Outcome
440.61 -X- _ I-Outcome
, -X- _ I-Outcome
p -X- _ I-Outcome
< -X- _ I-Outcome
0.05 -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
Group -X- _ I-Outcome
2 -X- _ I-Outcome
( -X- _ I-Outcome
GMT -X- _ I-Outcome
= -X- _ I-Outcome
331 -X- _ I-Outcome
, -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.02 -X- _ I-Outcome
) -X- _ I-Outcome
when -X- _ I-Outcome
compared -X- _ I-Outcome
with -X- _ I-Outcome
Group -X- _ I-Outcome
3 -X- _ I-Outcome
( -X- _ I-Outcome
GMT -X- _ I-Outcome
= -X- _ I-Outcome
86.11 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ O
A -X- _ O
novel -X- _ O
H7 -X- _ O
DNA -X- _ O
vaccine -X- _ O
was -X- _ O
safe -X- _ O
, -X- _ O
well-tolerated -X- _ O
, -X- _ O
and -X- _ O
immunogenic -X- _ O
when -X- _ O
boosted -X- _ O
with -X- _ O
H7N9 -X- _ O
monovalent -X- _ O
inactivated -X- _ O
vaccine -X- _ O
, -X- _ O
while -X- _ O
priming -X- _ O
for -X- _ O
higher -X- _ O
HAI -X- _ O
and -X- _ O
neutralizing -X- _ O
antibody -X- _ O
titers -X- _ O
than -X- _ O
H7N9 -X- _ O
monovalent -X- _ O
inactivated -X- _ O
vaccine -X- _ O
alone -X- _ O
. -X- _ O

